





What is mutation-driven therapy for MDS?

Mutation-driven therapy is treatment based on the mutations, or changes, in your genes. Some mutations called **driver mutations** help cancer develop.


Knowing what mutations you have helps your doctor predict how your body will respond to MDS treatment. In fact, it can help them choose a **treatment** that **targets** your specific mutations.



How can mutation-driven therapy help people with MDS?



People with MDS need better treatments



Stem cell transplant is the only treatment that can cure MDS



MDS has many different mutations and no single treatment works well for most people



Developing treatments that target various mutations could help more people survive MDS

Commonly mutated genes in people with MDS include:




<i>SF3B1</i>	<i>RUNX1</i>
<i>DNMT3A</i>	<i>SRSF2</i>
<i>TET2</i>	<i>IDH1</i>
<i>TP53</i>	<i>IDH2</i>
<i>ASXL1</i>	<i>U2AF1</i>

People with some of these mutations seem to have very **distinct characteristics** to their MDS.

Where is MDS mutation-driven therapy going?

The future involves using our knowledge of mutations in MDS to develop **increasingly precise treatments**.



Knowing your mutation profile is important for understanding your outlook and making treatment decisions.

For more information about MDS, visit:

www.YouAndMDS.com



Mechanisms in Medicine
Interactive Animated Medical Education

Developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

© Mechanisms in Medicine Inc. All rights reserved. Published 2022.

References:

1. American Cancer Society: Myelodysplastic syndromes. Causes, risk factors, and prevention. Available at: <https://www.cancer.org/cancer/myelodysplastic-syndrome/causes-risks-prevention.html>.
2. Platzbecker U. Treatment of MDS. *Blood*. 2019;133(10):1096-1107.
3. Malcovati L, Stevenson K, Papaemmanuil E, et al. *SF3B1*-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. *Blood*. 2020;136(2):157-170.
4. The Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.: You And MDS: An Animated Patient's Guide to Myelodysplastic Syndromes. Available at: www.YouAndMDS.com